Compare Ascendis Pharma A/S (ASND) vs Tapestry, Inc. (TPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Tapestry, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Tapestry, Inc. trades at $140.22 (market cap $28.43B). The key difference: Tapestry, Inc. is the larger of the two by market cap, and Tapestry, Inc. pays a 1.14% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TPR | |
|---|---|---|
Market Cap | $17.74B | $28.43B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $160.49 |
52-Week Low | $163.32 | $95.69 |
Enterprise Value | $18.11B | $31.29B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TPR trades at $140.73, up 0.57% today, with a bearish technical signal but strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $1.24. Valuation ratios are elevated (P/E 42.91, P/B 41.67), though profitability metrics like a 76.18% gross margin and 55.74% ROE remain robust. Recent news highlights digital growth and Gen Z engagement, with a $0.40 dividend paid in June 2026.
The outlook is mixed: bullish analyst consensus ($184.14 price target, 75.61% buy ratings) contrasts with technical bearishness and a high debt load. Key risks include sensitivity to consumer spending and execution of growth initiatives. Upside hinges on sustained earnings beats and margin expansion, while debt management and competitive pressures pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
